Daily Newsletter

20 November 2023

Daily Newsletter

20 November 2023

Combination contraceptive pill to be made available OTC in England 

As part of the UK Government and NHS’s primary care access recovery plan, the service aims to enhance healthcare accessibility.

Jenna Philpott November 17 2023

Women in England will be able to obtain the contraceptive pill directly from their local pharmacy without requiring a GP referral as of next month.  

To access the service, women can visit participating pharmacies for a confidential consultation with a pharmacist, who can make shared decisions with the person regarding their initial or ongoing supply of the contraceptive pill. For combined oral hormonal contraception, body mass index (BMI) and blood pressure measurements will be taken during the consultation. 

This NHS announcement comes over two years after the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) allowed two brands, Hana and Lovima, to be made available over the counter without a prescription. These contraceptive pills contained synthetic progesterone. The latest announcement covers combination pills that consist of synthetic estrogen and progesterone. The combined pill wasn’t included in the 2021 announcement, due to risks associated with the contraception to smokers aged over 35 years. 

Making the pill available to purchase over the counter (OTC) at pharmacies is expected to improve access to contraception for women who struggle to obtain it through traditional avenues, such as their GP or sexual health clinics. 

According to Ben Morris, a pharmacist who took part in a pilot of the scheme, anecdotal feedback has been “overwhelmingly positive”.

In the announcement accompanying the service, Morris highlighted the speed of the service, saying: “Even with the combined pill, where we need to take blood pressure, height, and weight, it’s quick, including when people first register. When it’s progesterone only, where we don’t have to do the tests like with the combined pill, it’s even quicker.” 

Across the Atlantic, the first OTC birth control pill Opill (norgestrel) was approved by the US Food and Drug Administration in July 2023. This marked a milestone after continued calls from charities and organisations in the US to bring birth control pills out from behind the pharmacy counter. 

Acute Renal Failure (ARF) - Market Landscape

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.